摘要
晚期肝癌和胆管癌由于频繁的局部浸润和转移而代表着预后不良的疾病。 这些癌症的有效治疗剂尚未建立。 溶瘤病毒(OVs)构成了一类新型的有前途的选择性抗癌药物,最近的研究阐明了其独特的特征。 而且,临床试验正在证明有希望的结果。 肝细胞癌(HCC)的临床前模型正在测试许多OV。 重组的惠氏痘苗病毒Pexa-Vec(pexastimogene devacirepvec,JX-594)已经在临床试验中证实了HCC安全性和有效性的初步证据。 其他OVs很少进入临床测试。 胆管癌临床前研究和临床试验相对较少。 在这篇综述中,我们介绍了用OVs治疗难治性肝癌的各种方法。
关键词: 基因治疗,胆囊癌,胆管癌,溶瘤病毒,腺病毒,病毒疗法。
图形摘要
Current Cancer Drug Targets
Title:Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers
Volume: 18 Issue: 2
关键词: 基因治疗,胆囊癌,胆管癌,溶瘤病毒,腺病毒,病毒疗法。
摘要: Advanced liver cancers and biliary cancers represent diseases with dismal prognosis because of frequent local invasion and metastasis. Effective therapeutic agents for these cancers have not been established. Oncolytic viruses (OVs) constitute a novel class of promising, selective anticancer agents and recent studies have elucidated their unique features. Moreover, clinical trials are demonstrating promising results. Numerous OVs are being tested in preclinical models of hepatocellular carcinoma (HCC). The lead agent Pexa-Vec (pexastimogene devacirepvec, JX-594), a recombinant Wyeth strain vaccinia virus, has demonstrated preliminary evidence of safety and efficacy for HCC in clinical trials. Few other OVs have entered clinical testing. Relatively few preclinical studies and clinical trials exist for biliary cancers. In this review, we introduce various approaches using OVs to treat the intractable hepatobiliary cancers.
Export Options
About this article
Cite this article as:
Oncolytic Virotherapy and Gene Therapy Strategies for Hepatobiliary Cancers, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170330123841
DOI https://dx.doi.org/10.2174/1568009617666170330123841 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Monitoring Therapy with Gene Expression Profiling Reveals Physiological Differences in Drug Action
Current Pharmaceutical Design microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology The Antimitotic Potential of PARP Inhibitors, An Unexplored Therapeutic Alternative
Current Topics in Medicinal Chemistry Leptin: The Prototypic Adipocytokine and its Role in NAFLD
Current Pharmaceutical Design Recent Development of Oridonin Derivatives with Diverse Pharmacological Activities
Mini-Reviews in Medicinal Chemistry Targeting Notch Pathway in Cancer Diagnostics and Therapeutics: An Emerging Approach
Recent Patents on Anti-Cancer Drug Discovery Liver Transplantation for Hepatocellular Carcinoma: Current Role and Future Opportunities
Current Pharmaceutical Design Signal Transduction Therapy: Challenges to Clinical Trial Design
Current Signal Transduction Therapy Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Dietary Antioxidants: Immunity and Host Defense
Current Topics in Medicinal Chemistry A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Synthesis, Characterization and Anti-hepatoma Activity of New Hederagenin Derivatives
Mini-Reviews in Medicinal Chemistry A Focus on Heme Oxygenase-1 (HO-1) Inhibitors
Current Medicinal Chemistry Synergistic Effect of α-Solanine and Cisplatin Induces Apoptosis and Enhances Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine Melatonin and Aromatase in Breast Cancer
Clinical Cancer Drugs HOXB7 and Hsa-miR-222 as the Potential Therapeutic Candidates for Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology Drug Targets in Herpes Simplex and Epstein Barr Virus Infections
Infectious Disorders - Drug Targets